GSE177054
Inhibition of CK1e potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer
In this study, we found that combination treatment of breast cells with CK1 inihbitor (D 4476) and CDK4/6 inhibitor (Ribociclib) exhibited greatly enhanced therapeutic efficacy than CDK4/6 inhiitor single treatment Overall design: RNA-seq study of human triple negative breast cancer cell line MDA-MB-231 with DMSO, CDK4/6 inihbitor (Ribociclib) single treatment, Ribociclib and CK1 inhibitor (D 4476) combination treatment for 48 hours